Maxwell Biosciences

About

Maxwell Biosciences is a biotechnology company based in Austin, Texas, founded in 2016. The company focuses on developing a synthetic immune system to address infectious diseases, including viruses, bacteria, fungi, and biofilm formations. Their technology aims to restore immunity and extend healthspan by tackling immunosenescence, which is associated with biological aging. The company specializes in creating synthetic small molecules that mimic natural immune system peptides. Their flagship technology, Claromer, produces drug candidates effective against a wide range of pathogens, including pan-coronavirus and pan-influenza. One of their lead candidates, MXB-22,510, has the potential to serve as a frontline therapy for various viral infections and may replace many existing antifungals and antibiotics. Maxwell Biosciences primarily serves the pharmaceutical industry and aims to enhance biodefense capabilities against pandemics. With a total funding of $10.8 million, the company has received support from organizations like DARPA and the National Institutes of Health, positioning itself as a leader in innovative solutions for global health security.